… this phase 2 study and its companion trial in patients hospitalized with Covid-19, 29 molnupiravir
was … The subsequent phase 3 component of this study sought to further assess whether …

… Our analysis does not support routine use of molnupiravir for COVID-19 treatment in … to
the study protocols (WHO scale 2–3). Another small Phase 3 single-centre study from China …

… and received molnupiravir 800 mg twice daily for 5 days for the treatment of … phase 2/3
randomized, double-blind, placebo-controlled trial that evaluated molnupiravir for the treatment …

… was designed to evaluate the antiviral efficacy of molnupiravir and was not powered to …
However, a Phase 2/3 study is ongoing to evaluate the effect of molnupiravir on symptom duration …

… Phase 2/3 studies showed molnupiravir effectiveness in mild … Molnupiravir initially emerged
as a possible treatment of … in this study and was found to be lowest in molnupiravir 800 mg …

… The phase 3 component of MOVe-OUT, a phase 2–3, double-blind, parallel-group,
randomized, placebo-controlled trial evaluating the safety and efficacy of molnupiravir in …

… Trials of molnupiravir have previously been done in largely unvaccinated participants …
Our trial provides an estimate of the effectiveness of molnupiravir in a multiply vaccinated …

… molnupiravir for the treatment of mild to moderate COVID-19 based on clinical markers and
the need for respiratory interventions and medical services from the phase … ) was a phase 2/3 …

… In a ferret model of SARS-CoV-2 infection, molnupiravir treatment completely blocked …
However, a phase 2/3 study is ongoing to evaluate the effect of molnupiravir on symptom duration …

… To assess the impact of molnupiravir treatment on COVID-19 … -reported symptoms data from
the phase 3 component of MOVe-… Phase 2/3 trial of molnupiravir for treatment of COVID-19 in …